When Cancer Loses Its Guards: Scientists Turn The Tumor's Immune System Against Itself

Researchers have discovered how to turn cancer's allies into its worst enemies. By eliminating tumor-protecting macrophages and activating the local immune system, a new form of immunotherapy has managed to destroy aggressive tumors and create a lasting response against cancer. This strategy could pave the way for more effective treatments against solid tumors.

The immune system has specialized cells that defend the body against infections and diseases, including cancer. Among these cells are macrophages, which normally help eliminate threats. However, within tumors, many macrophages end up being "reprogrammed" by the cancer itself. Instead of attacking the tumor, they begin to protect it, helping it grow and escape the body's defenses.

These "traitorous" macrophages, called tumor-associated macrophages, create an environment around the cancer that blocks the action of defense cells. This environment is known as the tumor microenvironment and acts as a shield, making many immunological treatments ineffective, especially in solid tumors, such as those of the lung and ovary.

In this study, scientists had an innovative idea: instead of directly attacking cancer cells, they decided to first eliminate the macrophages that help the tumor. To do this, they used immune system cells called T lymphocytes, genetically modified in the laboratory to specifically recognize and destroy the macrophages that support the cancer.

These modified cells were also "equipped" to release a substance that strongly stimulates the immune system. This substance acts as an alarm signal, attracting and activating other defense cells within the tumor.

The goal was not only to kill the harmful macrophages, but to completely transform the tumor environment from a place that protects the cancer into a hostile environment.

The tests were performed on experimental models of aggressive and metastatic cancer. The researchers applied small amounts of these modified cells, without the need for prior intensive treatments.

Surprisingly, the cells remained concentrated in the tumor, without causing serious side effects in other organs, and significantly increased the survival rate of the animals, with some showing complete disappearance of the cancer.

To understand how this worked, the scientists analyzed the tumors in great detail, observing which cells were present and how they behaved after treatment. They discovered that the macrophages that protected the cancer were replaced by macrophages that stimulate the immune response. Furthermore, specialized immune cells that kill cancer cells multiplied and became more active within the tumor.

The illustration shows how modified immune cells can transform the tumor environment. Before treatment, the tumor microenvironment is dominated by macrophages that suppress the immune response and protect the cancer. After the application of CAR-T cells targeted against these macrophages and programmed to release interleukin-12, the scenario changes: pro-tumor macrophages are eliminated or replaced by immune-stimulating macrophages, other defense cells are recruited and activated, and the tumor becomes recognized and destroyed. This process reprograms the tumor from a "cold" state, resistant to the immune system, to a "hot" state, vulnerable to immune attack, leading to the death of cancer cells.

Even after the number of modified cells decreased, the positive effect remained. The tumor continued to be attacked by the body's own immune system.

This shows that the strategy not only eliminates harmful cells but also re-educates the immune system to keep the cancer under control. These results indicate a promising path for treating solid tumors that are currently difficult to combat.

READ MORE:

Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growth

Jaime Mateus-Tique, Ashwitha Lakshmi, Bhavya Singh, Rhea Iyer, Alfonso R. Sánchez-Paulete, Chiara Falcomatà, Matthew Lin, Gvantsa Pantsulaia, Alexander Tepper, Trung Nguyen, Angelo Amabile, Gurkan Mollaoglu, Luisanna Pia, Divya Chhamalwan, Jessica Le Berichel, Hunter Potak, Marco Colonna, Alessia Baccarini, Joshua Brody, Miriam Merad, and Brian D. Brown

Cancer Cell. 22 January 2026

DOI: 10.1016/j.ccell.2025.12.021

Abstract:

Parkinson’s disease (PD) is a progressive neurodegenerative disorder. DNA repair dysfunction and integrated stress response (ISR) dysregulation have been implicated in PD pathophysiology, however, their role during the prodromal phase remains unclear. We analyzed longitudinal blood transcriptomic data from the Parkinson’s Progression Markers Initiative to assess DNA repair and ISR genes in healthy individuals, prodromal PD, and those with established PD. Logistic regression classifiers showed that DNA repair and ISR expression distinguished prodromal PD from healthy individuals, with accuracy peaking in later prodromal stages. In contrast, these pathways did not separate established PD from controls, suggesting a more prominent role early in progression. Gene expression variability in prodromal PD was high at baseline but decreased over time, indicating convergence as disease advances. Notably, 50% of DNA repair genes and 74% of ISR genes showed non-linear patterns, suggesting a transient adaptive response fading with progression. Feature importance analysis highlighted several predictors of prodromal PD, including ERCC6, PRIMPOL, NEIL2, and NTHL1. These findings indicate that DNA repair and ISR dysregulation are relevant in prodromal PD and may be biomarkers for early detection and intervention. Future research should validate these results in larger cohorts and evaluate diagnostic and therapeutic potential.